1. bookVolume 26 (2020): Issue 3 (August 2020)
Journal Details
License
Format
Journal
First Published
16 Feb 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma

Published Online: 13 Sep 2021
Page range: 137 - 144
Journal Details
License
Format
Journal
First Published
16 Feb 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Studies in recent years have shown that the immune system plays an important role in the prognosis of patients with different types of malignancies. The tumor immune microenvironment has been studied in various cancers in an attempt to find new antitumoral therapies. The therapeutic blockade of PD-1/PD-L1 has revolutionized the treatment of oncological pacients, with anti-PD-L1 monoclonal antibodies having remarkable results in malignant melanoma, cervical, renal and lung cancer. In laryngeal cancer, few reports are available on the immune microenvironment and PD-L1 expression. Considering these, we retrospectively review 23 laryngeal cancer patients with laryngectomy performed in the Otorhinolaryngology Department - Emergency County Clinical Hospital St Andrew Constanta. The aim of our research was to evaluate the immunohistochemical expression of PD-L1, using combined positive score which includes both viable tumoral cells and intratumoral lymphocytes, as well as the level of CD8 intratumoral lymphocytes and to analise the corelation between these markers and the clinicopathological characteristics of the pacients, in order to set these two parameters, in the near future, as new biomarkers. PD-L1 expression was shown to be a prognostic factor for disease-free survival in laryngeal cancer patients (p = 0.006) and was higher in tumors with elevated CD8 lymphocyte levels, with a significant correlation correlation between the two parameters (p = 0.019). The level of CD8 lymphocytes was also a predictive factor for free-disease survival, correlated with patient smoker status (p = 0.04), being higher in non-smoking patients.

Keywords

1. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. Search in Google Scholar

2. Hoesli R, Birkeland AC, Rosko AJ et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018; 77:83-89. Search in Google Scholar

3. Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res. 2016;22(3):704-713. Search in Google Scholar

4. Ismail M, Wakiel HE l., Ghany DA, Shakweer MM, Lotfy A, Gaballah AM. 132P - Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial. Ann Oncol. 2019;30:xi49. Search in Google Scholar

5. Jia YQ, Yang B, Wen LL, Mu WX, Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging (Albany NY). 2019;11(2):501-522. Search in Google Scholar

6. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. Search in Google Scholar

7. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. Search in Google Scholar

8. IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. Search in Google Scholar

9. Karpathiou G, Casteillo F, Giroult JB, et al. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immunosuppressive pathways and clinicopathologic characteristics. Oncotarget. 2017;8(12):19310-19322. Search in Google Scholar

10. Cojocaru Oana, Aschie Mariana, Mocanu Liliana, Baltatescu Gabriela IzabelaLaryngeal primary malignant melanoma: a case report, Rom J Morphol Embryol 2015, 56(4):1513–1516 Search in Google Scholar

11. Harasymczuk M, Gooding W, Kruk-Zagajewska A, Wojtowicz J, Dworacki G, Tomczak H, et al. Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg. 2013 Mar;270(3):1105–14. Search in Google Scholar

12. Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3ţ, CD4ţ and CD8ţ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast., Indian J Med Res 2014;140:361–9. Search in Google Scholar

13. Badoual C. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clin Cancer Res. 2006; 12: 465–72. Search in Google Scholar

14. Rittà M, Landolfo V, Mazibrada J, De Andrea M, Dell’Oste V, Caneparo V, Peretti A, Giordano C, Pecorari G, Garzaro M, Landolfo S. Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer. New Microbiol. 2013; 36: 133–44. Search in Google Scholar

15. Zandberg DP, Strome SE. The role of the PD-L1/PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology. 2014; p. 627–32. Search in Google Scholar

16. Takada K, Toyokawa G, Okamoto T, Akamine T, Takamori S, Katsura M, et al. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria. Anticancer Res. 2016 Jul;36(7):3409–12. Search in Google Scholar

17. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73: 1733–41. Search in Google Scholar

18. Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One. 2015; 10: e0142656. Search in Google Scholar

19. Cho YA, Yoon HJ, Lee J Il, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011; 47: 1148–53. Search in Google Scholar

20. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28:682–8. Search in Google Scholar

21. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013;8(6):e65821. Search in Google Scholar

22. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013;1:54–63. Search in Google Scholar

23. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233–42. Search in Google Scholar

24. Balermpas P, Rodel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163ţ macrophages in primary tumour and CD11bţ myeloid cells in recurrences. Br J Cancer 2014;111:1509–18. Search in Google Scholar

25. Gooden MJ, de Bock GH, Leffers N, Daemen T, NijmanHW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93–103. Search in Google Scholar

26. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–74 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo